Aligos Therapeutics announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis, MASH. Screening of subjects has begun at clinical study sites across the U.S. “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile. We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH. The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos Therapeutics. “This is an exciting time in the MASH space with the first drug recently approved, but we believe there is still a need for additional treatment options. We look forward to sharing topline HERALD data in Q4 this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALGS:
- Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences
- Aligos Therapeutics Reports Recent Business Progress andĀ Fourth Quarter and Full Year 2023 Financial Results
- Aligos Therapeutics to host conference call
- Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- Aligos Therapeutics, Inc. (ALGS) Q4 Earnings Cheat Sheet